Erasca, Inc. - Common Stock, $0.0001 par value per share (ERAS)

CUSIP: 29479A108

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
+3,400,866
SEC-reported price per share
$14.66
Number of holders
17
Value change
+$49,856,149
Number of buys
9
Number of sells
6
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
355,466,212

Security key

29479A108

Report period

Q3 2026

Institutions

17

Top holders

10

Ownership snapshot

Top reported holders of ERAS - Erasca, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
City Hill, LLC
Disclosed value leader
City Hill, LLC
Comparable rows
9/15
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 10% 6 rows are not safely comparable across share classes. 13D/G row: City Hill, LLC Showing 1-6 of 15 holder rows.

Quick read

City Hill, LLC leads the comparable SEC ownership view at 10%.

9 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens City Hill, LLC's linked filing trail.
Comparable ownership Top 5
City Hill, LLC 10%
T. Rowe Price Investment Manageme... 6.8%
Venrock Healthcare Capital Partne... 5.3%
Frazier Life Sciences Public Fund... 5.3%
RTW INVESTMENTS, LP 5.2%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
City Hill, LLC
13D/G
Jonathan E. Lim
10%
Reported 13D/G · 30 Jun 2026
$697,595,331
36,968,486 shares
$0 30 Jun 2026
T. Rowe Price Investment Management, Inc.
13F 13D/G
Company
6.8%
Reported 13D/G · 31 Mar 2026
$388,125,000
21,185,839 shares
— 30 Jun 2026
Venrock Healthcare Capital Partners III, L.P.
13D/G
5.3%
Reported 13D/G · 31 Mar 2026
$284,405,616
16,382,812 shares
$0 31 Mar 2026
Frazier Life Sciences Public Fund, L.P.
13D/G
5.3%
Reported 13D/G · 30 Jun 2025
$21,355,029
15,038,753 shares
-$10,702,679 30 Jun 2025
RTW INVESTMENTS, LP
13F 13D/G
Company
5.2%
Reported 13D/G · 31 Mar 2026
$328,784,533
17,946,754 shares
— 30 Jun 2026
Logos Global Management LP
13F 13D/G
Company
4.8%
Reported 13D/G · 30 Sep 2025
$222,588,000
12,150,000 shares
— 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
17
Shares
4,484,818
Rows available
17
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
256
Q3 2026 holders
17
Holder diff
-239
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .